ストックスクリーナーアプリを入手
12.17
7.70%
0.87
アフターアワーズ：
12.30
0.13
+1.07%
前日終値:
$11.30
開ける：
$11.3
24時間の取引高:
2.02M
Relative Volume:
1.14
時価総額：
$1.38B
収益：
$655.35M
当期純損益:
$-136.23M
株価収益率:
-9.9566
EPS:
-1.2223
ネットキャッシュフロー:
$-75.68M
1週間 パフォーマンス:
+12.79%
1か月 パフォーマンス:
+0.91%
6か月 パフォーマンス:
-14.17%
1年 パフォーマンス:
-26.06%
1日の値動き範囲:
$11.30
$12.44
1週間の範囲:
$10.40
$12.44
52週間の値動き範囲:
$9.82
$20.06
Novocure Ltd Stock (NVCR) Company Profile
Compare NVCR vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
12.17 | 1.29B | 655.35M | -136.23M | -75.68M | -1.2223 |
ABT
Abbott Laboratories
|
101.56 | 175.59B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
341.24 | 132.47B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.10 | 113.14B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
64.61 | 94.85B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
78.20 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | 開始されました | Ladenburg Thalmann | Buy |
| 2024-12-02 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-10-16 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-08-28 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | 開始されました | SVB Securities | Outperform |
| 2023-07-31 | アップグレード | Evercore ISI | Underperform → In-line |
| 2023-06-07 | アップグレード | Wedbush | Underperform → Neutral |
| 2023-05-16 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-01-06 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2022-11-29 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2022-05-16 | 開始されました | H.C. Wainwright | Buy |
| 2022-02-08 | 開始されました | Loop Capital | Buy |
| 2022-02-02 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-01-20 | アップグレード | Truist | Hold → Buy |
| 2022-01-03 | アップグレード | Evercore ISI | Underperform → In-line |
| 2021-07-01 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-14 | ダウングレード | Wedbush | Neutral → Underperform |
| 2021-01-25 | 繰り返されました | Piper Sandler | Overweight |
| 2020-09-23 | 開始されました | Northland Capital | Outperform |
| 2020-09-18 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | ダウングレード | Truist | Buy → Hold |
| 2020-06-01 | 再開されました | Oppenheimer | Perform |
| 2020-05-01 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-04-09 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2020-03-05 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-07-29 | アップグレード | SunTrust | Hold → Buy |
| 2019-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-07-26 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-03-20 | 開始されました | SunTrust | Hold |
| 2018-11-02 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | 開始されました | Evercore ISI | Outperform |
| 2018-04-18 | 繰り返されました | Mizuho | Buy |
| 2018-02-23 | 繰り返されました | Mizuho | Buy |
| 2017-05-24 | アップグレード | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | 繰り返されました | Wedbush | Outperform |
| 2016-01-19 | 開始されました | Barclays | Underweight |
| 2015-12-02 | 開始されました | Deutsche Bank | Hold |
すべてを表示
Novocure Ltd (NVCR) 最新ニュース
Is NovoCure’s (NVCR) Leadership Consolidation Clarifying Its Innovation Strategy Or Complicating Governance Signals? - simplywall.st
NovoCure Ltd (NVCR) Stock Up 5.4% and Still Undervalued -- GF Sc - GuruFocus
NVCR SEC FilingsNovocure 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing NovoCure (NVCR) Valuation After Prolonged Share Price Weakness And Undervalued Narrative - simplywall.st
NovoCure Unifies Clinical And Innovation Roles As Market Discounts Persist - Sahm
NovoCure Ltd (NVCR) Stock Down 3.8% -- Now Undervalued? GF Score: 66/100 - GuruFocus
NovoCure Limited Increases Compensation for Dr. Uri Weinberg Upon Appointment as Chief Medical Officer - Minichart
Novocure increases executive compensation as Uri Weinberg takes on dual roles By Investing.com - Investing.com South Africa
Novocure increases executive compensation as Uri Weinberg takes on dual roles - Investing.com
NovoCure appoints Uri Weinberg as Chief Medical Officer alongside Chief Innovation Officer - TradingView — Track All Markets
NovoCure (NASDAQ: NVCR) boosts pay as Uri Weinberg assumes CMO duties - Stock Titan
NovoCure (BSP:N2VC34) Net Investment Income - GuruFocus
NovoCure (BSP:N2VC34) Other Assets for Insurance Companies - GuruFocus
NovoCure (BSP:N2VC34) Dividend Yield % : 0.00% (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Other Net Income (Loss) : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) 6-1 Month Momentum % : N/A% (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Cash Flow from Discontinued Operations : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) PEG Ratio : N/A (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Gross-Profit-to-Asset % : 49.36% (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Shiller PE Ratio : (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Purchase Of Investment : R$-4,539 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Operating Income : R$-851 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Minority Interest : R$0.00 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) 3-1 Month Momentum % : N/A% (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Investments And Advances : R$0 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Non Operating Income : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) 1-Year Sharpe Ratio : N/A (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Retained Earnings : R$-7,040 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Interest and Commission Paid - GuruFocus
NovoCure (BSP:N2VC34) Inventories, Other : R$-0 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Forward Dividend Yield % : 0.00% (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Graham Number : R$N/A (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) PE Ratio (TTM) : At Loss (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Cyclically Adjusted PS Ratio : (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Other Long-Term Liabilities : R$0 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Other Current Assets : R$106 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Gross Property, Plant and Equipment : R$1,180 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Total Operating Expense : R$3,550 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Purchase Of Business : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Sale Of Business : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Dividend Payout Ratio : 0.00 (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Cyclically Adjusted Price-to-FCF : (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Net Policyholder Benefits/Claims - GuruFocus
NovoCure (BSP:N2VC34) Policyholder Funds - GuruFocus
BSP:N2VC34 EBITDA: R$-581 Mil | Possible Value Trap - GuruFocus
NovoCure (BSP:N2VC34) Goodwill : R$0 Mil (As of Dec. 2025) - GuruFocus
BSP:N2VC34 OCF Yield %: -3.95 | Possible Value Trap - GuruFocus
NovoCure (BSP:N2VC34) Other Operating Expense : R$-0 Mil (TTM As of Dec. 2025) - GuruFocus
BSP:N2VC34 EV-to-EBITDA: 0.72 | Possible Value Trap - GuruFocus
BSP:N2VC34 Accounts Payable: R$667 Mil | Possible Value Trap - GuruFocus
BSP:N2VC34 FCF Margin %: -13.13% | Possible Value Trap - GuruFocus
Novocure Ltd (NVCR) 財務データ
収益
当期純利益
現金流量
EPS
2.40%
0.00%
大文字化:
|
ボリューム (24 時間):